MoonLake Immunotherapeutics AG

Contributing Author

Recent Articles by MoonLake Immunotherapeutics AG

May-10	MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results MLTX GlobeNewswire
Mar-28	MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting MLTX GlobeNewswire
Feb-22	MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results MLTX GlobeNewswire
Feb-02	MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day MLTX GlobeNewswire
Jan-08	MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day MLTX +27.02% GlobeNewswire
Nov-05	MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering MLTX GlobeNewswire
Nov-05	MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody Sonelokimab MLTX GlobeNewswire
Sep-28	MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody sonelokimab MLTX GlobeNewswire
Aug-05	MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update MLTX GlobeNewswire
May-12	MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update MLTX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)